In silico analysis of an envelope domain III-based multivalent fusion protein as a potential dengue vaccine candidate.

ABSTRACT:

Purpose

Dengue virus infection is now a global problem. Currently, there is no licensed vaccine or proven antiviral treatment against this virus. All four serotypes (1-4) of dengue virus can infect human. An effective dengue vaccine should be tetravalent to induce protective immune responses against all four serotypes. Most of dengue vaccine candidates are monovalent, or in the form of physically mixed multivalent formulations. Recently envelope protein domain III of virus is considered as a vaccine candidate, which plays critical roles in the most important viral activities. Development of a tetravalent protein subunit vaccine is very important for equal induction of immune system and prevention of unbalanced immunity. Here, we have presented and used a rational approach to design

SUBMITTER: Fahimi H 

PROVIDER: S-EPMC4742598 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature